Sydney, Australia · Founded 2019 · Privately Held (backing)
Operator of a radiopharmaceutical company intended for developing alpha therapies for cancer patients. AdvanCell is based in Sydney, Australia and was founded in 2019. Its last reported valuation was $165 million in Jun 2025. It has raised $132 million.
Last reported valuation
$165.0M
Oct 2026
Priced at
—
Total raised
$132.3M
Last round
—
Cap table — not yet on record
AdvanCell's share-class structure hasn't surfaced in our sources yet. Cap tables are assembled from certificates of incorporation, round filings, and disclosures as they land.
Pro members can request priority coverage with a 48-hour turnaround.
Free account
More of AdvanCell with a free account
·The complete investor list: 18 names
·Watch AdvanCell: the Monday email on marks, rounds and moves
